Paliperidone
Brand names: Invega, Paliperidone Er
At a glance
- Medicare prescriptions, 2024
- 306,882
- Medicare drug cost
- $61.1M
- Average cost per prescription
- $199
- Clinicians who prescribed it
- 10,759
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
1. INDICATIONS AND USAGE Paliperidone is an atypical antipsychotic agent indicated for Treatment of schizophrenia Adults: Efficacy was established in three 6-week trials and one maintenance trial. Adolescents (ages 12-17): Efficacy was established in one 6-week trial. Treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and/or antidepressants. Efficacy was established in two 6-week trials in adult patients.
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Paliperidone extended-release tablets are not approved for the treatment of patients with dementia-related psychosis.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Psychiatry 36.1%
- Psychiatric Nurse Practitioners 34.6%
- Nurse Practitioners 9.7%
- Family Medicine 5.0%
- Internal Medicine 4.9%
- Physician Assistants 4.8%
- Child & Adolescent Psychiatry 1.9%
- Geriatric Medicine 0.8%
- General Practice 0.5%
- Neurology 0.3%
- Addiction Medicine 0.3%
- Hospitalist 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 10% from 2019 to 2024.
Biggest change by state since 2019
- Michigan +36%
- Minnesota +24%
- Pennsylvania +23%
- Washington +21%
- Illinois +21%
- Louisiana (smallest change) −12%
- Tennessee (smallest change) −7%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 3 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Ajanta Pharma USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 1.5 mg | brown round tablet, 8 mm | PL1 |
| 3 mg | white round tablet, 8 mm | PL2 |
| 6 mg | yellow round tablet, 8 mm | PL3 |
| 9 mg | pink round tablet, 8 mm | PL4 |
Ani Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 1.5 mg | orange round tablet, 7 mm | 032 |
| 3 mg | white round tablet, 7 mm | 033 |
| 6 mg | brown round tablet, 7 mm | 034 |
| 9 mg | pink round tablet, 7 mm | 035 |
Bryant Ranch Prepack
| Strength | Looks like | Imprint |
|---|---|---|
| 3 mg | white round tablet, 9 mm | EP 3 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $57,821 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Janssen Pharmaceuticals, Inc $37,833
- Janssen Scientific Affairs, LLC $19,989
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Feb 2022 · The Harvard Drug Group · Class II
Failed Dissolution Specifications
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.